84.55
-0.33%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $3.27bn
- Last close × shares
- Volume
- 799.7k
- Shares, 20 Nov 2026
About Dianthus Therapeutics
From its filings with the US Securities and Exchange Commission
Dianthus Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DNTH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.0m and a net loss of $162.3m. At that date it held total assets of $530.9m and shareholders' equity of $493.4m.
Our second clinical-stage candidate, DNTH212, is a first and potentially best-in-class, bifunctional fusion protein that targets plasmacytoid dendritic cell (“pDC”) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. DNTH212 is also designed with the potential for patient friendly convenient, infrequent, self-administered S.C. injections suitable for a pre-filled pen.
Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. The active form of C1s is generated during complement activation by cleavage of the inactive proC1s. As a validated complement target in the autoimmune and inflammatory field, C1s inhibition prevents further progression of the classical pathway cascade. Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (“PK”) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Latest on Dianthus Therapeutics
Our reporting
- Dianthus Therapeutics falls 3.45% in Wednesday's session
- Dianthus Therapeutics falls 2.87% in Tuesday's session
- Dianthus Therapeutics falls 2.46% in Monday's session
- Dianthus Therapeutics rises 3.56% in Thursday's session
- Dianthus Therapeutics rises 4.61% in Monday's session
- Dianthus Therapeutics rises 3.64% in Friday's session
Next results
Due on 8 Mar 2027. Analysts expect earnings of -0.96 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Dianthus Therapeutics's ticker?
Dianthus Therapeutics trades as DNTH on its US listing, under ISIN US2528281080.
What was Dianthus Therapeutics's last closing price?
84.55 on 20 Nov 2026. The figure is in USD and is never converted.
When does Dianthus Therapeutics next report results?
Results are expected on 8 Mar 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.